Artivion To Present New Clinical Data For On-X Aortic Heart Valve And AMDS At 104th AATS Annual Meeting
Artivion, Inc. Common Stock -0.41% Pre
Artivion, Inc. Common Stock AORT | 26.53 26.53 | -0.41% 0.00% Pre |
5-Year Real-World Safety and Efficacy Data from On-X Aortic Heart Valve Low INR Post-Market Study Demonstrate Even Better Patient Outcomes Than Predicted by the PROACT IDE Study
Late-Breaking 30-Day Data from AMDS PERSEVERE Trial Demonstrate Positive Aortic Remodeling Outcomes and Zero DANE Tears